What are the therapeutic effects and potential adverse effects of hydroxychloroquine in treating mast cell disorders such as cutaneous mastocytosis or mast cell activation syndrome?

Hydroxychloroquine Shows Promise for Mast Cell Disorders but is Not Standard Therapy

Hydroxychloroquine is not included in established treatment guidelines for mast cell activation syndrome (MCAS) or cutaneous mastocytosis, but emerging research suggests it may reduce mast cell survival, interfere with degranulation, and decrease pro-inflammatory mediator production 1. The standard first-line approach remains H1 and H2 antihistamines, mast cell stabilizers like cromolyn sodium, and leukotriene inhibitors 2, 3.

Current Guideline-Based Treatment Framework

The 2019 AAAAI guidelines for MCAS management prioritize:

• H1 antihistamines (cetirizine, fexofenadine at 2-4 times FDA-approved doses) for pruritus, flushing, urticaria, and tachycardia 2
• H2 antihistamines (famotidine, ranitidine) for gastrointestinal symptoms and vascular manifestations 2, 3
• Cromolyn sodium for diarrhea, abdominal pain, nausea, and potentially cutaneous symptoms 3
• Leukotriene inhibitors (montelukast) for bronchospasm and GI symptoms, particularly if urinary LTE4 levels are elevated 2

Pediatric cutaneous mastocytosis guidelines from 2011 emphasize the same antihistamine-based approach, noting that cytoreductive therapy is strongly discouraged except in life-threatening aggressive variants 3.

Emerging Evidence for Hydroxychloroquine

A 2018 study demonstrated that hydroxychloroquine reduced long-term survival of primary human mast cells, interfered with lysosome function, led to accumulation of non-functional tryptase in granules, and decreased pro-inflammatory mediator production in four patients (two with cutaneous mastocytosis, two with MCAS) 1. A 2020 study in rosacea (which involves mast cell activation) showed hydroxychloroquine suppressed LL37-induced mast cell activation, including inflammatory factor release, chemotaxis, degranulation, and calcium influx, partly via inhibiting KCa3.1-mediated calcium signaling 4.

Critical Safety Considerations from FDA Labeling

Before considering hydroxychloroquine, recognize these serious risks 5:

• Cardiac toxicity: Cardiomyopathy, QT prolongation, ventricular arrhythmias including torsades de pointes. Avoid in patients with congenital/acquired QT prolongation, cardiac disease, bradycardia, or electrolyte abnormalities
• Irreversible retinal toxicity: Risk increases with doses ≥5 mg/kg actual body weight, duration >5 years, renal impairment. Requires baseline ophthalmologic exam within first year, then annual monitoring after 5 years (or annually if high-risk)
• Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome, AGEP 5, 6, 7
• Hepatotoxicity: Particularly in porphyria cutanea tarda patients
• Hematologic toxicity: Myelosuppression, hemolysis in G6PD deficiency
• Neuropsychiatric effects: Including suicidality
• Hypoglycemia: Severe cases reported

Clinical Decision Algorithm

For newly diagnosed MCAS or cutaneous mastocytosis:

1. Start with guideline-recommended therapies: non-sedating H1 antihistamines at high doses (2-4× standard) plus H2 antihistamines 2, 3
2. Add cromolyn sodium for GI symptoms 3
3. Consider leukotriene inhibitors if bronchospasm or refractory GI symptoms 2
4. Reserve corticosteroids for acute flares or refractory symptoms (0.5 mg/kg/d with slow taper) 2

For refractory cases not responding to standard therapy:

Hydroxychloroquine may be considered as an off-label option, but only after:

• Comprehensive cardiac evaluation (ECG, electrolytes, assessment for structural heart disease)
• Baseline ophthalmologic examination
• Screening for G6PD deficiency
• Liver function testing
• Discussion of serious adverse effect risks with patient

Contraindications to hydroxychloroquine in mast cell disorders:

• Pre-existing cardiac conduction abnormalities or QT prolongation
• Psoriasis (may precipitate severe flare) 5
• Porphyria 5
• G6PD deficiency
• Concurrent use of other QT-prolonging medications

Important Caveats

The evidence for hydroxychloroquine in mast cell disorders consists of one small case series (n=4) 1 and mechanistic studies in related conditions 4. This is insufficient to establish efficacy or safety compared to guideline-recommended therapies with decades of clinical experience. The 2026 MCAS review emphasizes that consensus-2 diagnostic criteria have improved recognition and treatment, but does not mention hydroxychloroquine as an established therapy 8. Similarly, the 2025 management yardstick for indolent mastocytosis and MCAS does not include hydroxychloroquine in treatment algorithms 9.

The risk-benefit ratio favors established therapies (antihistamines, cromolyn) as first-line treatment, with hydroxychloroquine reserved only for carefully selected refractory cases where potential benefits outweigh substantial cardiac, ocular, and dermatologic risks.